225P Initial data from the DELIVER trial of DYNE-251 in males with DMD Mutations amenable to Exon 51 skipping
L. De Waele, M. Guglieri, N. Deconinck, Satyajit Ray, K. Flanigan, A. Dugar(Sarepta Therapeutics (United States)), Chris Mix, Martin Naylor, Dajiang Wang, Perry B. Shieh(Boston Children's Hospital), M. Lorentzos, Wildon Farwell(Biogen (United States)), H. Phan(Rare Disease Therapeutics (United States)), Craig Campbell(Children's Hospital of Western Ontario)
Cited by 1
Related Papers
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy
|JAMA Neurology|2020|387
Recessive truncating titin gene, <i>TTN</i> , mutations presenting as centronuclear myopathy
|Neurology|2013|217